insulin typically gained weight [1] [2] [3] . Metabolic improvements with exenatide b.i.d. were maintained in a subset of patients treated for 3.5 years [4] .
While randomized, controlled trials are the reference standard for assessing the efficacy and safety of therapy, large, observational studies are necessary to determine how glucose-lowering medications are used in clinical practice and to evaluate their effectiveness and safety in this setting [5, 6] CHOICE is the first European observational study conducted specifically to address this lack of evidence. CHOICE is an ongoing, prospective cohort study designed to assess the time to a significant subsequent change in therapy among patients who initiate their first injectable glucoselowering therapy with either exenatide b.i.d. or insulin (the only injectable treatments available when this study commenced) in Europe. The study also aimed to describe the characteristics of patients with T2DM initiating injectable therapy, factors associated with treatment changes, and clinical outcomes and common adverse events observed over 24 months. CHOICE is being conducted in six European countries and will be completed in 2012. This paper reports the baseline characteristics of enrolled patients and measured variables associated with injectable treatment regimen.
METHODS

Design and Patients
CHOICE is a prospective, multinational, noninterventional observational study being The following strategy was used to achieve the required number of patients in each cohort without intervening in treatment decisions made during normal clinical practice: once a cohort within a participating country was filled, investigating physicians were asked to stop enrollment into that cohort and to continue enrolling patients only into the other treatment cohort, as and when they initiate patients on that treatment according to their usual practice.
Statistical Analysis
All patients eligible at baseline were included in the analyses. Baseline patient data were reported using descriptive statistics and 95% CI where appropriate. For continuous variables mean, SD, median, minimum, maximum, and quartiles were calculated. Absolute numbers and percentages (including missing values) were given for categorical variables. Percountry analyses were also performed.
Univariate analyses were performed to compare all baseline patient characteristics between the two cohorts (overall population and per country). Continuous variables were analyzed using t tests, analyses of variance Logistic regression was also used to derive propensity scores from baseline data (0.10 threshold for between-cohort differences).
The propensity score estimates the probability that a patient will be assigned to a treatment group based on baseline characteristics (score range 0-1). Propensity score analysis was used to assess comparability of the treatment cohorts [11] . For this analysis all eligible baseline data were included. Missing data were imputed with the overall mean or median for continuous variables, and most frequent category for categorical variables, in order to give a conservative estimate. Patients were matched 1:1 by country based on the propensity score and optimal matching to identify matched subsets from the two cohorts. All P values are reported without multiplicity adjustments. 
RESULTS
Between
Demographic and Clinical Characteristics
Overall, patients had a mean age of 61 ± 10 years, BMI of 32.3 ± 6.6 kg/m 2 and 
Comorbidity and Concomitant
Medications
Patients initiating exenatide b.i.d. had a statistically higher incidence of comorbidities than patients initiating insulin (P = 0.0014), i.e., a diagnosis of hypertension (69.5% vs. 65.3%, respectively) and hyperlipidemia (54.5% vs. 48.7%, respectively). Overall, 85.5% of patients were using at least one concomitant patients were statistically significantly more likely to have used weight-lowering medications than insulin patients (4.6% vs. 1.5%, respectively; P\0.0001).
Resource Use
Overall, 79.4% of patients self-monitored blood glucose, using a mean of 9.6 ± 8.3 test strips/ week. There were no statistically significant differences between the cohorts in the number of contacts with healthcare professionals in the 6 months prior to baseline (Table 1) . were characterized by: younger age; higher body weight, BMI, and waist circumference; higher diastolic blood pressure, lower total and LDL cholesterol levels; shorter time since diabetes diagnosis; and better glycemic control. A lower Table 3 Overall propensity scores and distribution by quintile for each cohort 
Factors Associated with Injectable Treatment Regimen and Propensity Score
